Immatics’ cell therapy has been linked to a 56% objective response rate (ORR) among 32 heavily pretreated patients with metastatic melanoma. The biotech previously shared progression-free survival ...
LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback